NeoMotion is a wearable fetal monitoring platform designed to deliver continuous, real-time insights for every pregnancy — especially in low-resource settings where access to conventional CTG is limited.
Hospital-based CTG systems are expensive, bulky, power-dependent, and require trained operators. NeoMotion is being designed to bridge the gap between hospital-grade monitoring and real-world maternal care in rural clinics, homes, and emergency transport.
Fetal distress and reduced movement may be recognized after a critical window has passed.
Rural facilities need simpler early-warning signals to support faster escalation and triage.
Limited power, connectivity, staffing, and device availability restrict traditional monitoring.
The first development focus is fetal heart rate and fetal movement, with maternal physiologic monitoring as modular capabilities. The platform emphasizes low-power operation, simplified user experience, and offline functionality when connectivity is limited.
Attach the soft, medical-grade adhesive patch to the maternal abdomen.
Doppler and motion sensors acquire fetal heart rate and fetal movement data continuously.
Embedded processing filters noise, extracts patterns, and evaluates predefined thresholds.
Local visual/audio alerts and wireless transmission support earlier clinical review.
The story should stay credible: early detection of fetal compromise in high-burden settings may reduce delay-related adverse outcomes. Pilot endpoints should include feasibility, referral timing, delivery outcomes, stillbirth rates, usability, compliance, and system reliability.
*Based on the uploaded conservative impact model; not a clinical claim.
NeoMotion is led by physicians combining frontline clinical insight, global health experience, and disciplined execution to build a maternal–fetal monitoring platform for the communities that need it most.
Co-Founder & Chief Executive Officer (CEO)
Dr. Bargo is the clinical inventor behind NeoMotion and brings deep experience with maternal health challenges in Chad and across Africa. He leads the company’s vision, government partnerships, clinical pilot strategy, and global expansion mission to reduce preventable fetal and maternal mortality.
Co-Founder & Chief Operating Officer (COO)
Dr. Hassan is a U.S.-based Pulmonary and Critical Care physician. He oversees operations, regulatory strategy, engineering coordination, strategic partnerships, and commercialization efforts to bring NeoMotion from concept to validated clinical deployment.
A disciplined medical-device roadmap protects the IP, reduces regulatory risk, and creates the structure needed for grants, clinical partnerships, and future investment.
Delaware C-Corp, IP assignment, founder vesting, MOH endorsement, pilot sites, ethics pathway.
Target Gates, UNICEF, WHO, USAID, NIH Fogarty, and global maternal-health funders.
Build research-grade Doppler patch, app display, local alerts, and validation workflow.
Compare against standard CTG, document usability, outcomes, safety, and reliability.
NeoMotion is positioned for a government-supported pilot with grant funding, clinical validation, and eventual licensing or strategic manufacturing partnership.
For pilot partnerships, engineering collaboration, grant development, investor interest, or strategic manufacturing discussions, contact the NeoMotion founding team.
Clinical collaboration • Global health pilot • Engineering • Investment